Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, announced that it secured €9.3 million in state funding under the Innovations in Biotherapies and Bioproduction call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Launched in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation. Its goal is to develop novel approaches to modulating Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has also developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, intending to develop antibody-based candidate drugs to disable Treg function and restore an effective anti-tumor immune response.
Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals in June 2020, establishing a three-year research collaboration with an option agreement. And since its founding, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During the Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
Last year, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
KEY QUOTE:
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
- Christophe Quéva, CEO of Egle Therapeutics
